Identification and Validation of Immune Implication of R-Spondin 1 and an R-Spondin 1-Related Prognostic Signature in Esophagus Cancer
View abstract on PubMed
Summary
This summary is machine-generated.R-spondin 1 (RSPO1) expression is significantly decreased in esophageal cancer (ESCA), impacting immune cell infiltration. RSPO1-related gene signatures show promise as predictive biomarkers for ESCA immunotherapy.
Area Of Science
- Oncology
- Immunology
- Molecular Biology
Background
- R-spondin 1 (RSPO1) is a secretory-activating protein and a potential therapeutic target in various cancers.
- Understanding RSPO1's role in esophageal cancer (ESCA) is crucial for developing targeted therapies.
Purpose Of The Study
- To establish a robust RSPO1-related gene signature specific to ESCA.
- To investigate the association between RSPO1 expression and immune cell infiltration in ESCA.
- To develop a prognostic model for ESCA patients based on RSPO1 expression.
Main Methods
- Analysis of RSPO1 expression in ESCA tissues and cell lines using TCGA and GTEx databases.
- Single-sample gene set enrichment analysis (ssGSEA) to assess immune cell abundance.
- KEGG, GO, and GSEA for pathway enrichment analysis.
- Development and validation of prognostic nomograms and risk scores.
Main Results
- RSPO1 expression was significantly downregulated in ESCA tissues and cell lines compared to normal controls.
- ESCA exhibited decreased activated dendritic cells and increased macrophages and naive B cells.
- RSPO1 was associated with key tumor and immune-related pathways.
- A validated RSPO1-related gene signature served as an independent prognostic biomarker for ESCA.
Conclusions
- RSPO1 plays a critical role in regulating tumor immunity in ESCA.
- RSPO1 is a potential target for immunotherapeutic interventions in ESCA.
- The RSPO1-related gene signature is a promising predictive biomarker for ESCA.

